Travere Therapeutics (NASDAQ:TVTX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Travere Therapeutics (NASDAQ:TVTX) in a report issued on Wednesday,Benzinga reports. HC Wainwright currently has a $47.00 price target on the stock. HC Wainwright also issued estimates for Travere Therapeutics’ FY2026 earnings at ($0.25) EPS, FY2027 earnings at $0.95 EPS, FY2028 earnings at $2.54 EPS and FY2029 earnings at $3.28 EPS.

Other analysts also recently issued reports about the company. Scotiabank reaffirmed an “outperform” rating on shares of Travere Therapeutics in a research report on Thursday, August 7th. Wedbush increased their price objective on Travere Therapeutics from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Thursday, August 7th. Wall Street Zen raised Travere Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, September 1st. Finally, Citigroup reissued a “buy” rating on shares of Travere Therapeutics in a report on Sunday, August 10th. Thirteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Travere Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $33.43.

Travere Therapeutics Stock Performance

Shares of TVTX opened at $21.64 on Wednesday. The company has a current ratio of 2.00, a quick ratio of 1.98 and a debt-to-equity ratio of 9.50. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -10.61 and a beta of 0.79. The stock has a 50 day moving average of $16.83 and a 200 day moving average of $17.35. Travere Therapeutics has a 12 month low of $10.64 and a 12 month high of $25.29.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.14. The company had revenue of $94.84 million during the quarter, compared to the consensus estimate of $100.18 million. Travere Therapeutics had a negative return on equity of 717.68% and a negative net margin of 50.64%.Travere Therapeutics’s revenue was up 111.5% on a year-over-year basis. During the same period last year, the business posted ($0.65) earnings per share. As a group, sell-side analysts forecast that Travere Therapeutics will post -1.4 earnings per share for the current year.

Hedge Funds Weigh In On Travere Therapeutics

A number of large investors have recently made changes to their positions in the stock. Armistice Capital LLC boosted its holdings in shares of Travere Therapeutics by 20.6% in the first quarter. Armistice Capital LLC now owns 8,872,000 shares of the company’s stock worth $158,986,000 after acquiring an additional 1,514,000 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Travere Therapeutics by 27.4% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company’s stock worth $41,203,000 after acquiring an additional 599,102 shares during the period. Driehaus Capital Management LLC boosted its holdings in shares of Travere Therapeutics by 24.8% in the first quarter. Driehaus Capital Management LLC now owns 2,767,693 shares of the company’s stock worth $49,597,000 after acquiring an additional 549,718 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Travere Therapeutics by 36.7% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 2,174,213 shares of the company’s stock worth $37,875,000 after acquiring an additional 583,836 shares during the period. Finally, Emerald Advisers LLC boosted its holdings in shares of Travere Therapeutics by 0.7% in the second quarter. Emerald Advisers LLC now owns 2,091,360 shares of the company’s stock worth $30,952,000 after acquiring an additional 14,187 shares during the period.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.